Comparison of efficacy of 2 220 MBq versus 3 700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 5, 2010, Pages 560-563

  Fish, S A ^a   Basu, S ^b,c   Alavi, A ^b   Mandel, S J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c TATA MEMORIAL HOSPITAL   (India)

Author keywords

Carcinoma, papillary; Iodine 131 anti B1 antibody; Thyroglobulin; Thyroid neoplasms

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; RADIOACTIVE IODINE;

ABLATION THERAPY; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER INVASION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; STATISTICAL SIGNIFICANCE; THYROID CANCER; THYROID PAPILLARY CARCINOMA; TREATMENT DURATION; CELL DIFFERENTIATION; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RADIATION RESPONSE; RETROSPECTIVE STUDY; THYROID TUMOR; TRANSPORT AT THE CELLULAR LEVEL;

ABLATION TECHNIQUES; ADULT; BIOLOGICAL TRANSPORT; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 79251492069     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mazzaferri EL. Thyroid remnant I-131 ablation for papillary and follicular thyroid carcinoma. Thyroid 1997;7:265-71.
2. Regulatory guide 8.39. Release of patients administered radioactive materials. U.S. Nuclear Regulatory Commission. Washington, DC: Office of Nuclear Regulatory Research; 1997.
3. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of I-131 for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77:2574-80.
4. Johansen K, Woodhouse NJY, Odugbesan O. Comparison of 1 073 MBq and 3 700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991;32:252-4.
5. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987;12:500-2.
6. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of "ablation of thyroid remnants: with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 1984;25:1287-93.
7. Mazzaferri EL. Radioiodine and other treatment and outcomes. In: Braverman LE, Utiger RD, editors. The Thyroid. Philadelphia, PA: Lippincott Williams & Wilkins; 2000. p. 917.
8. McCowen KD, Adler RA, Ghaed N, Verdon T, Hofeldt FD. Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 1976;61:52-8.
9. DeGroot J, Reilly M. Comparison of 30 and 50 mCi doses of iodine-131 for thyroid ablation. Ann Int Med 1982;96:51-3.
10. Samuel AM, Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994;35:1944-50.
11. Maxon HR 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS et al. Radioiodine-131 therapy for well-differentiated thyroid cancer - A quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:1132-6.
12. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1 073 MBq and 3 700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991;32:252-4.
13. Roos DE, Smith JG. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma - A critique. Int J Radiat Oncol Biol Phys 1999;44:493-5.
14. Brown AP, Chen J, Hitchcock YJ, Szabo A, Schrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-15.
15. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-44.